# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $15...
Under the terms of the agreement, Beacon will have the right to evaluate, for a 12-month period, the AAV204 capsid for potentia...
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating...
Stifel analyst Dae Gon Ha initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Targ...
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and lowers the price ...